As the US proceeds with sweeping adjustments to its vaccine schedules, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccines throughout the global health crisis and has concentrated on potential fatalities after COVID-19 immunization in her short position at the Food and Drug Administration.
Scheduled Shifts to Pediatric Vaccine Schedule
Public health authorities had intended to reveal major revisions to the pediatric immunization program in December, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with a large portion of the global community with no evidence for benefit. The planned update has been delayed until the coming year.
Rather than the director of the vaccine center, Dr. Høeg is listed to address the audience at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.
A Shift at the Agency
The acting appointment may indicate a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.
Dr. Høeg has frequently advocated for ending certain pediatric shot schedules in the US in order to be more in line with Denmark's approach, a nation with universal health coverage and a population about the size of Wisconsin’s.
In her initial statements, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – instead of medication approval.
Questions Over Expertise
Høeg has no apparent background in pharmaceutical research, oversight or leadership, which has been typical for previous leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.
“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in running a large organization. She is not an expert in drug approvals.”
Previous directors of CBER would “understand regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that former directors who headed the center have had.”
CDER has an immense range of responsibilities at the FDA, the former commissioner pointed out.
“Many people just pays attention on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and more, and each of these need to be looked after,” she explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”
Additionally, a substantial administrative component to the job, which oversees more than 5,000 employees. “It is a massive management job, if you perform it correctly,” the former official concluded.
Official Statement and Disputed Policies
When asked about questions about Høeg’s fitness for the role and whether this selection signifies greater collaboration among FDA leaders on immunizations, a press secretary responded that the “questions are based on flawed presumptions”.
“Her resume aligns with the functions of her role,” the representative stated, citing the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.
As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a controversial expedited therapy clearance system that apparently troubled her predecessors. “By what process are these medications being chosen for this voucher program? Who makes the choices?” Howard questioned. “There’s a lot of secrecy happening at the regulatory body right now.”
Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of most medications, aside from vaccines.”
Documented Track Record on Vaccines
With vaccines, Dr. Høeg has a more documented, if troubling, track record, some experts have noted. She published a study using unconfirmed public submissions to assess the incidence of myocarditis following Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are riskier than they are.
Included in her “wish list” for the incoming administration included altering regulations for new vaccines and ending “non-essential” immunizations, she stated post-election on a podcast. At the FDA, Dr. Høeg has according to sources proposed preventing young men from receiving COVID-19 vaccines.
“She is an complete true believer who starts off with her conclusions and reverse-engineers to retrofit the evidence in a extremely misleading, untruthful way,” Dr. Howard argued.
Taking Control and a “Push for Payback”
Dr. Høeg joined fellow dissenters, {like|
